Viking is in the midst of a Phase 2a dosing trial of VK2735, with a data readout expected in the second half of the year. The company is expected to launch a Phase 3 trial of VK2735 in injectable ...

The company's GIP/GLP-1 agonist, VK2735, appears undifferentiated, facing intense competition from existing and emerging obesity treatments. Plans to launch VK2735 with an auto-injector could ...

Viking Therapeutics stock skidded Wednesday despite the "encouraging" speed with which the company enrolled patients in an obesity study.

Viking Therapeutics (VKTX) announced the completion of subject enrollment in its Phase 2 clinical trial of the oral tablet formulation of ...

"As with our previous Phase 2 study of subcutaneous VK2735, interest in participating in the Phase 2 VENTURE-Oral study was high and drove an efficient rate of enrollment," said Brian Lian ...

The agreement provides Viking with sufficient long-term supply of both subcutaneous and oral VK2735 product forms to support a potential multi-billion-dollar annual product opportunity.

Per the terms, Viking has secured dedicated manufacturing capacity to support the large-scale production of VK2735. The deal includes an annual supply commitment for multiple metric tons of the ...

The agreement provides Viking with sufficient long-term supply of both subcutaneous and oral VK2735 product forms to support a potential multi-billion-dollar annual product opportunity.